BioSapien is a biotechnology company focused on the development of a drug delivery platform, designed to direct chemotherapy precisely by targeting the site of cancerous cells. BioSapien's lead product is the MediChip™ platform, an extended-release dosage form engineered to allow for reduced dose-limiting toxicities and increased local bioavailability, while seeking to significantly reduce hospital and insurance burden through unique on-the-go delivery.
